Novartis raises full year core operating income guidance12 hours agoNovartis raised its full-year core operating income guidance to low single-digit growth after strong third-quarter demand for key cancer and multiple sclerosis drugs.Novartis raises full year core operating income guidancereutersTopic tracking2026-09-10Major Novartis Shareholder Calls for Board Shake-Up After Drug Trial Setbacks2026-09-10Novartis investors turn spotlight on M&A after trial setbacks2026-10-26Novartis raises full year core operating income guidance
ChemBrief